Caption: Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), today announced that the results of the company's Phase I/II clinical trial testing the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury will be presented on

Credit: Pluristem Therapeutics